Turning Point offers a glimpse at its cancer drug’s promise
Turning Point Therapeutics, in the middle of an all-important clinical trial, released some early data on its targeted cancer therapy, positive results that might speed up the FDA process.
As STAT’s Matthew Herper reports, Turning Point’s drug shrank the tumors of 86% of lung cancer patients who hadn’t received prior treatment. For patients previously treated with another targeted therapy, that number was 67%, and for those who’d received a targeted drug and chemotherapy, the rate was 40%.
The results are an early look at an ambitious clinical trial that Turning Point hopes will turn its drug, repotrectinib, into a treatment for cancers with a variety of genetic signatures. Meanwhile, the FDA is allowing Turning Point to pool data from an earlier study of repotrectinib with data from the current study, which could allow it to file an application for approval sooner, the company said.
Read more.
As STAT’s Matthew Herper reports, Turning Point’s drug shrank the tumors of 86% of lung cancer patients who hadn’t received prior treatment. For patients previously treated with another targeted therapy, that number was 67%, and for those who’d received a targeted drug and chemotherapy, the rate was 40%.
The results are an early look at an ambitious clinical trial that Turning Point hopes will turn its drug, repotrectinib, into a treatment for cancers with a variety of genetic signatures. Meanwhile, the FDA is allowing Turning Point to pool data from an earlier study of repotrectinib with data from the current study, which could allow it to file an application for approval sooner, the company said.
Read more.
.png)
No hay comentarios:
Publicar un comentario